Shares of Eli Lilly were taking a 6.9% hit toward a two-month low in recent trading, enough to make them the S&P 500's biggest decliner. The problem is that the drug giant provided fourth-quarter ...

The S&P 500 advanced 0.92% to 6,067.70, with technology shares seeing the biggest gains among sectors. The Technology Select ...

Eli Lilly (NYSE: LLY) stock was the picture of health on Friday. Shares of the massive American pharmaceutical company rose ...

The Eli Lilly and Company-Bond has a maturity date of 3/15/2027 and offers a coupon of 5.5000%. The payment of the coupon will take place 2.0 times per biannual on the 15.09.. At the current price ...

January 2025 saw strong gains in US and international equities, led by Health Care sector performance and concerns about inflation. Click for my monthly recap.

During the last three months, 7 analysts shared their evaluations of Eli Lilly LLY, revealing diverse outlooks from bullish to bearish. The table below summarizes their recent ratings, showcasing ...

Wells Fargo lowered the firm’s price target on Eli Lilly (LLY) to $970 from $1,000 and keeps an Overweight rating on the shares. The firm ...

Eli Lilly and Company discovers ... Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It provides oncology products ...

Lilly (LLY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.